Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992

A decade of immune-checkpoint inhibitors in cancer therapy

Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349

CTLA-4: a moving target in immunotherapy

Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233

EASL Clinical Practice Guidelines: Drug-induced liver injury

Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003

Neoantigens: promising targets for cancer therapy

Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946

Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade

House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790

Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia

Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747

Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants

Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636

Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response

Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616

The hallmarks of successful anticancer immunotherapy

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570

TIGIT as an emerging immune checkpoint

Harjunpää, H., & Guillerey, C. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13407 · Cited by 552

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review

Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Das, R., Bar, N., Ferreira, M., Newman, A. M., Zhang, L., Bailur, J. K., Bacchiocchi, A., Kluger, H., Wei, W., Halaban, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96798 · Cited by 423

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

Teraoka, S., Fujimoto, D., Morimoto, T., Kawachi, H., Ito, M., Sato, Y., Nagata, K., Nakagawa, A., Otsuka, K., Uehara, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.022 · Cited by 375

Bacterial outer membrane vesicles as a platform for biomedical applications: An update

Li, M., Zhou, H., Yang, C., Wu, Y., Zhou, X., Liu, H., & Wang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.031 · Cited by 370

Stress and cancer: mechanisms, significance and future directions

Eckerling, A., Ricon-Becker, I., Sorski, L., Sandbank, E., & Ben-Eliyahu, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00395-5 · Cited by 348

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

Danlos, F.-X., Voisin, A.-L., Dyevre, V., Michot, J.-M., Routier, E., Taillade, L., Champiat, S., Aspeslagh, S., Haroche, J., Albiges, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.008 · Cited by 300

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0585-1 · Cited by 294

Targeting the gut microbiota for cancer therapy

Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280

Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity

Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., Chan, D., Dusza, S., Motzer, R. J., Rosenberg, J. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02141 · Cited by 241

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

Iyer, P. C., Cabanillas, M. E., Waguespack, S. G., Hu, M. I., Thosani, S., Lavis, V. R., Busaidy, N. L., Subudhi, S. K., Diab, A., & Dadu, R. (2018) · Thyroid · doi:10.1089/thy.2018.0116 · Cited by 238

Therapeutic depletion of CCR8 + tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy

Van Damme, H., Dombrecht, B., Kiss, M., Roose, H., Allen, E., Van Overmeire, E., Kancheva, D., Martens, L., Murgaski, A., Bardet, P. M. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001749 · Cited by 205

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

Kobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Tsunekawa, T., Onoue, T., Takagi, H., Hagiwara, D., Ito, Y., Morishita, Y., et al. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2017-00432 · Cited by 203

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau3259 · Cited by 190

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

Suzman, D. L., Pelosof, L., Rosenberg, A., & Avigan, M. I. (2018) · Liver International · doi:10.1111/liv.13746 · Cited by 189

Endocrine side effects of cancer immunotherapy

Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177

Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

Frohne, C. C., Llano, E. M., Perkovic, A., Cohen, R. D., & Luke, J. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0484-x · Cited by 171

Incidence and risk factors of drug‐induced liver injury

Li, X., Tang, J., & Mao, Y. (2022) · Liver International · doi:10.1111/liv.15262 · Cited by 158

Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance

Raschi, E., Gatti, M., Gelsomino, F., Ardizzoni, A., Poluzzi, E., & De Ponti, F. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00738-6 · Cited by 157

Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity

Choi, Y., Lichterman, J. N., Coughlin, L. A., Poulides, N., Li, W., Del Valle, P., Palmer, S. N., Gan, S., Kim, J., Zhan, X., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abo2003 · Cited by 132

Targeting immune checkpoints in hematological malignancies

Salik, B., Smyth, M. J., & Nakamura, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00947-6 · Cited by 113

Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system

Raschi, E., Mazzarella, A., Antonazzo, I. C., Bendinelli, N., Forcesi, E., Tuccori, M., Moretti, U., Poluzzi, E., & De Ponti, F. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00632-w · Cited by 101

Delivery Strategies for Immune Checkpoint Blockade

Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800424 · Cited by 90

Immune-mediated drug-induced liver injury: immunogenetics and experimental models

Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87

Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis

Li, M., Wong, D., Vogel, A. S., Sack, J. S., Rahma, O. E., Hodi, F. S., Zucker, S. D., & Grover, S. (2022) · Hepatology · doi:10.1002/hep.32215 · Cited by 73

Trial watch: immune checkpoint blockers for cancer therapy

Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73

Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells

Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68

Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review

Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02699-1 · Cited by 30